Squarepoint Ops LLC lessened its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 59.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,864 shares of the company's stock after selling 17,245 shares during the quarter. Squarepoint Ops LLC's holdings in SpringWorks Therapeutics were worth $429,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Boxer Capital Management LLC acquired a new stake in SpringWorks Therapeutics during the 4th quarter worth $123,620,000. Capital International Investors grew its holdings in shares of SpringWorks Therapeutics by 92.7% during the fourth quarter. Capital International Investors now owns 2,361,746 shares of the company's stock worth $85,330,000 after purchasing an additional 1,136,079 shares during the last quarter. Pictet Asset Management Holding SA increased its position in shares of SpringWorks Therapeutics by 24.2% during the fourth quarter. Pictet Asset Management Holding SA now owns 2,391,412 shares of the company's stock worth $86,402,000 after purchasing an additional 465,494 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of SpringWorks Therapeutics by 6.6% in the 4th quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company's stock valued at $258,650,000 after purchasing an additional 445,593 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of SpringWorks Therapeutics in the 4th quarter valued at about $10,527,000.
SpringWorks Therapeutics Price Performance
Shares of NASDAQ:SWTX remained flat at $46.80 during trading on Friday. The stock had a trading volume of 3,119,418 shares, compared to its average volume of 2,296,686. SpringWorks Therapeutics, Inc. has a 1-year low of $28.21 and a 1-year high of $62.00. The firm's fifty day moving average price is $43.41 and its two-hundred day moving average price is $43.62. The company has a market cap of $3.53 billion, a price-to-earnings ratio of -13.45 and a beta of 0.70.
SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.30). The firm had revenue of $49.09 million during the quarter, compared to analyst estimates of $64.19 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. On average, equities research analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
SWTX has been the topic of a number of research reports. Wedbush restated a "neutral" rating and set a $47.00 price target (down previously from $81.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Barclays restated an "equal weight" rating and set a $47.00 target price (down from $63.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. Cowen downgraded shares of SpringWorks Therapeutics to a "hold" rating in a research report on Tuesday, April 29th. HC Wainwright reiterated a "neutral" rating and set a $47.00 price target (down previously from $74.00) on shares of SpringWorks Therapeutics in a research note on Wednesday, April 30th. Finally, TD Cowen reissued a "hold" rating and set a $47.00 price objective (down from $66.00) on shares of SpringWorks Therapeutics in a research report on Tuesday, April 29th. Seven analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $52.57.
Get Our Latest Stock Report on SWTX
SpringWorks Therapeutics Company Profile
(
Free Report)
SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Further Reading
Before you consider SpringWorks Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SpringWorks Therapeutics wasn't on the list.
While SpringWorks Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
